Investors

LOVALTECH: PIONEERING A BREAKTHROUGH IN MUCOSAL DELIVERY

Lovaltech is a deep-tech biotech company working at the cutting edge of clinical research. It was established through the collaboration of the University of Tours and INRAE. Its core asset, LVT-NEXUS, is a patent-protected mucosal delivery platform that can be used with various types of biomolecules. The company's first product, the LVT-001 vaccine for treating and preventing SARS-CoV-2 infection, has completed Phase 1 clinical trials, demonstrating favourable safety and tolerability profiles that support continued evaluation. Phase 2 is scheduled to start in November 2026, evaluating immunogenicity in comparison to an injectable vaccine. We are preparing for our next funding round in 2027.

Key strengths of Lovaltech:

• Clinical evidence: - Phase 1 of LVT-001 has been completed and Phase 2 is scheduled to start in November 2026.
• Intellectual property: robust protection of our products and platform.
• Strong financial foundation: over €18 million raised.
• Multiple sources of value: proprietary products, licensing and co-development.
• Pipeline: discovery programs targeting other infectious diseases and beyond.
• Governance: a strategic board and a scientific committee of experts.

LVT-NEXUS, our mucosal delivery platform

Lovaltech is deploying LVT-NEXUS, a versatile mucosal delivery platform designed to deliver, protect and release biomolecules within the mucosa.

Applied to vaccination, LVT-NEXUS induces protective immune responses, essential for stop transmission in various infectious diseases conditions. The unique value of our technology lies in its ability to create an immune shield at the mucosal level, where infection begins.
Our approach has broad commercial applications, particularly in oncology, infectious diseases and allergies.

LVT-001, our first product

LVT-001 is the first product developed using LVT-NEXUS. It serves as our clinical proof of concept. Phase 1 has been completed, demonstrating a favourable safety and tolerability profile. Phase 2 will begin in November 2026, aiming to confirm the superiority of the mucosal immune response.

A business model that generates value in three different ways.

1. Proprietary products: capitalising on the value of products developed with LVT-NEXUS, beginning with LVT-001.
2. Platform licensing: providing access to LVT-NEXUS and LVT-ME for third-party candidates.
3. Co-development: share the development of new products.

“Lovaltech is not just developing vaccines, we're reshaping the future of global health security."